Global patent index - EP 1071751 A1

EP 1071751 A1 2001-01-31 - TRANSGENIC MAMMALS EXPRESSING MUTANT GP IIIa

Title (en)

TRANSGENIC MAMMALS EXPRESSING MUTANT GP IIIa

Title (de)

TRANSGENE SÄUGETIERE, DIE MUTIERTES GPIIIa EXPRIMIEREN

Title (fr)

MAMMIFERES TRANSGENIQUES EXPRIMANT UN GP IIIa MUTANT

Publication

EP 1071751 A1 (EN)

Application

EP 99918586 A

Priority

  • US 9908285 W
  • US 11551698 P

Abstract (en)

[origin: WO9953032A1] The present invention relates to mammals into which foreign DNA has been introduced or in which various modifications or substitutions have been made to an integrin beta subunit, thereby generating transgenic or genetically-engineered non-human mammals. In particular, the present invention provides a transgenic mammal in which the endogenous GP IIIa gene has been replaced with an altered or mutant GP IIIa gene in which one or all of the phosphorylatable cytoplasmic tyrosine residues have been replaced with non-tyrosine residues such as phenylalanine. Since the platelets in the blood of the resultant transgenic mammals expressing the altered or mutant GP IIIa cannot undergo tyrosine phosphorylation to the extent that it occurs in wild-type mammals, these genetically-engineered animals provide a critical tool for assessing the importance of the phosphorylation reaction for platelet function. The invention is also useful for studying the effect of the mutant GP IIIa integrin subunit on biological processes other than platelet formation.

IPC 1-7 (main, further and additional classification)

C12N 5/10; A01K 67/027; A61K 49/00; C07K 14/705

IPC 8 full level (invention and additional information)

A01K 67/027 (2006.01); A61K 45/00 (2006.01); A61P 7/02 (2006.01); C07K 14/705 (2006.01); C12N 15/09 (2006.01); C12N 15/85 (2006.01)

CPC (invention and additional information)

C12N 15/8509 (2013.01); A01K 67/0275 (2013.01); C07K 14/70557 (2013.01); A01K 2217/072 (2013.01); A01K 2227/105 (2013.01); A01K 2267/03 (2013.01); C12N 2800/30 (2013.01)

Citation (search report)

See references of WO 9953032A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

EPO simple patent family

WO 9953032 A1 19991021; AU 3646299 A 19991101; CA 2325817 A1 19991021; EP 1071751 A1 20010131; IL 138873 D0 20011125; JP 2002511249 A 20020416

INPADOC legal status

2004-06-09 [18D] DEEMED TO BE WITHDRAWN

- Ref Legal Event Code: 18D

- Effective date: 20031031

2003-01-08 [RAP1] TRANSFER OF RIGHTS OF AN EP PUBLISHED APPLICATION

- Owner name: MILLENNIUM PHARMACEUTICALS, INC.

- Ref Legal Event Code: RAP1

2001-12-05 [17Q] FIRST EXAMINATION REPORT

- Ref Legal Event Code: 17Q

- Effective date: 20011019

2001-01-31 [17P] REQUEST FOR EXAMINATION FILED

- Ref Legal Event Code: 17P

- Effective date: 20001018

2001-01-31 [AK] DESIGNATED CONTRACTING STATES:

- Ref Legal Event Code: AK

- Designated State(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE